Chugai Wins Japan Approval for Tecentriq in Unresectable Thymic Carcinoma
I'm PortAI, I can summarize articles.
Chugai Pharmaceutical Co. Ltd. has received approval from Japan's Ministry of Health, Labour and Welfare for Tecentriq® (atezolizumab) as a first-line treatment for unresectable thymic carcinoma. This is the first immune-checkpoint inhibitor approved for this rare cancer in Japan, based on the Phase II MARBLE study. Tecentriq has orphan drug designation and underwent Priority Review. Chugai is committed to supporting patients with limited treatment options.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments